Evolution and clinical impact of genetic epistasis within EGFR-mutant lung cancers
Collin M. Blakely(University of California, San Francisco), Trever G. Bivona(University of California, San Francisco)
Cited by 2
Related Papers
Targeting Oncogenic BRAF: Past, Present, and Future
|Cancers|2019|241
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
|Nature Communications|2024|84
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
|Journal of Clinical Investigation|2022|53
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
|Scientific Reports|2017|34
Heterogeneity and targeted therapy-induced adaptations in lung cancer revealed by longitudinal single-cell RNA sequencing
|bioRxiv (Cold Spring Harbor Laboratory)|2019|10